Sugi Predict

Sugi Predict / Compounds / SCHEMBL3552873

SCHEMBL3552873

SCHEMBL3552873

COC(=O)[C@H]1C[C@@H](F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PEPD P12955 1/20 0.48
▸ XPNPEP1 Q9NQW7 1/20 0.48
▸ PTPN1 P18031 1/20 0.43
▸ MMP2 P08253 2/20 0.42
▸ ANPEP P15144 2/20 0.42
▸ NR1H2 P55055 2/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ CYP1A2 P05177 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ DPP4 P27487 6/20 0.37
▸ DPP8 Q6V1X1 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476146 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL91557 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL4250662 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3643891 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL2995724 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3554330 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL18591298 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL19219868 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL29827776 0.91 NR1H2 (0.39) PEPDXPNPEP1PTPN1NR1H2NR1H3
SCHEMBL29947782 0.91 NR1H2 (0.39) PEPDXPNPEP1PTPN1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4413985-B1 PHARMACEUTICAL COMPOUNDS NXERA PHARMA UK LTD (GB) 2026-05-06 — — EP disclosed
EP-4714446-A2 PHARMACEUTICAL COMPOUNDS Nxera Pharma UK Limited (GB) 2026-03-25 — — EP disclosed
WO-2025059040-A1 MUTANT KRAS MODULATORS AND USES THEREOF NEWAVE PHARMACEUTICAL INC. (US) 2025-03-20 — — WO disclosed
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
EP-4413985-A2 PHARMACEUTICAL COMPOUNDS Nxera Pharma UK Limited (GB) 2024-08-14 — — EP disclosed
EP-3406609-B1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LTD (GB) 2024-06-26 — — EP disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-08-07 — — US disclosed
WO-2012162635-A1 METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-11-29 — — WO disclosed
US-20100174096-A1 Methods for Production of Optically Active Fluoropyrrolidine Derivatives IM&T RESEARCH, INC. (US) 2010-07-08 — — US disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 — — US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 — — US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 — — US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 — — US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 — — EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 — — EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174096-A1 Methods for Production of Optically Active Fluoropyrrolidine Derivatives QDPR, FDPS, DPYD PEPD 190/4885XPNPEP1 1225/4885PTPN1 4849/4885
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF GRM5, GRIK5, GRM2 PEPD 1735/4885XPNPEP1 2552/4885PTPN1 2693/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 PEPD 77/4885XPNPEP1 222/4885PTPN1 4552/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PEPD 2713/4885XPNPEP1 2892/4885PTPN1 486/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PEPD 203/4885XPNPEP1 428/4885PTPN1 2663/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PEPD 2713/4885XPNPEP1 2892/4885PTPN1 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.